Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
about
Real-time monitoring of human blood-brain barrier disruptionDelivery of chemotherapeutics across the blood-brain barrier: challenges and advances.Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoMurine models of B-cell lymphomas: promising tools for designing cancer therapiesSystems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model.A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement.Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder.Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.[F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [F]FDG in human xenograft models
P2860
Q30359368-E45DFC26-DDC5-400D-96BF-427C0CF11B3FQ30859319-3455586A-0423-4E5C-99B3-A6FDE58BD67FQ33759799-6C908D75-086E-400B-8117-34AAA3CB7CE8Q34943963-BCEC890E-A25C-4BD0-BF62-00A92C1606B6Q35779492-3A00D12C-5A23-4A9F-8841-0F79AA2D7C57Q38163336-D74A6018-5AB3-40B3-A5A2-72B2A960A7FBQ38927027-3F52E3FF-3B8C-4CDB-893C-56CE178E5C03Q39146340-72D4D165-96ED-4F9F-AADC-C2A5A51A280FQ39279101-0C19C35B-4273-4118-9D95-337E36297AABQ45072965-8AA60804-E24D-4DF4-861E-CAD5EBD7D8FDQ48806049-276A49B7-C49E-4DC5-9E30-2140D6147F44Q51295662-87C5C352-0B4B-462A-BC15-065BD8702F82Q58788935-E4BE0B88-C37E-4ED9-B018-05AF7B77ADA4
P2860
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@ast
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@en
type
label
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@ast
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@en
prefLabel
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@ast
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@en
P2093
P2860
P1476
Imaging and therapy with ritux ...... ntral nervous system lymphoma.
@en
P2093
Dale F Kraemer
Leslie L Muldoon
Michael A Pagel
Nancy D Doolittle
Seth J Lewin
P2860
P304
P356
10.1158/1078-0432.CCR-10-2923
P407
P577
2011-03-08T00:00:00Z